187 related articles for article (PubMed ID: 28440948)
1. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.
Yin H; Meng T; Shu L; Mao M; Zhou L; Chen H; Song D
Chem Biol Drug Des; 2017 Nov; 90(5):892-899. PubMed ID: 28440948
[TBL] [Abstract][Full Text] [Related]
2. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
3. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
6. Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy.
Song Q; Wang X; Wang Y; Liang Y; Zhou Y; Song X; He B; Zhang H; Dai W; Wang X; Zhang Q
Mol Pharm; 2016 Jan; 13(1):190-201. PubMed ID: 26629710
[TBL] [Abstract][Full Text] [Related]
7. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
8. Redox-responsive polymer-drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy.
Su Y; Hu Y; Du Y; Huang X; He J; You J; Yuan H; Hu F
Mol Pharm; 2015 Apr; 12(4):1193-202. PubMed ID: 25751168
[TBL] [Abstract][Full Text] [Related]
9. Controlled and Targeted Drug Delivery by a UV-responsive Liposome for Overcoming Chemo-resistance in Non-Hodgkin Lymphoma.
Li H; Guo K; Wu C; Shu L; Guo S; Hou J; Zhao N; Wei L; Man X; Zhang L
Chem Biol Drug Des; 2015 Oct; 86(4):783-94. PubMed ID: 25739815
[TBL] [Abstract][Full Text] [Related]
10. Folate-containing reduction-sensitive lipid-polymer hybrid nanoparticles for targeted delivery of doxorubicin.
Wu B; Yu P; Cui C; Wu M; Zhang Y; Liu L; Wang CX; Zhuo RX; Huang SW
Biomater Sci; 2015 Apr; 3(4):655-64. PubMed ID: 26222425
[TBL] [Abstract][Full Text] [Related]
11. Bioreducible carboxymethyl dextran nanoparticles for tumor-targeted drug delivery.
Thambi T; You DG; Han HS; Deepagan VG; Jeon SM; Suh YD; Choi KY; Kim K; Kwon IC; Yi GR; Lee JY; Lee DS; Park JH
Adv Healthc Mater; 2014 Nov; 3(11):1829-38. PubMed ID: 24753360
[TBL] [Abstract][Full Text] [Related]
12. Development of novel polymeric micellar drug conjugates and nano-containers with hydrolyzable core structure for doxorubicin delivery.
Mahmud A; Xiong XB; Lavasanifar A
Eur J Pharm Biopharm; 2008 Aug; 69(3):923-34. PubMed ID: 18430550
[TBL] [Abstract][Full Text] [Related]
13. pH and redox dual responsive nanoparticle for nuclear targeted drug delivery.
K C RB; Thapa B; Xu P
Mol Pharm; 2012 Sep; 9(9):2719-29. PubMed ID: 22876763
[TBL] [Abstract][Full Text] [Related]
14. Coordinated pH/redox dual-sensitive and hepatoma-targeted multifunctional polymeric micelle system for stimuli-triggered doxorubicin release: Synthesis, characterization and in vitro evaluation.
Wang L; Tian B; Zhang J; Li K; Liang Y; Sun Y; Ding Y; Han J
Int J Pharm; 2016 Mar; 501(1-2):221-35. PubMed ID: 26851356
[TBL] [Abstract][Full Text] [Related]
15. Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics.
Lin CJ; Kuan CH; Wang LW; Wu HC; Chen Y; Chang CW; Huang RY; Wang TW
Biomaterials; 2016 Jun; 90():12-26. PubMed ID: 26974704
[TBL] [Abstract][Full Text] [Related]
16. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy using core-shell nanoparticles through the self-assembly of HPMA-based copolymers and degradable polyester.
Jäger E; Jäger A; Chytil P; Etrych T; Ríhová B; Giacomelli FC; Stěpánek P; Ulbrich K
J Control Release; 2013 Jan; 165(2):153-61. PubMed ID: 23178950
[TBL] [Abstract][Full Text] [Related]
18. Preparation of pH-Sensitive Dextran Nanoparticle for Doxorubicin Delivery.
Wang B; Liu P; Shi B; Gao J; Gong P
J Nanosci Nanotechnol; 2015 Apr; 15(4):2613-8. PubMed ID: 26353472
[TBL] [Abstract][Full Text] [Related]
19. Balancing the stability and drug release of polymer micelles by the coordination of dual-sensitive cleavable bonds in cross-linked core.
Deng H; Zhang Y; Wang X; Jianhuazhang ; Cao Y; Liu J; Liu J; Deng L; Dong A
Acta Biomater; 2015 Jan; 11():126-36. PubMed ID: 25288518
[TBL] [Abstract][Full Text] [Related]
20. Reduction Responsive Nanovesicles Derived from Novel α-Tocopheryl-Lipoic Acid Conjugates for Efficacious Drug Delivery to Sensitive and Drug Resistant Cancer Cells.
Maiti B; Kumar K; Moitra P; Kondaiah P; Bhattacharya S
Bioconjug Chem; 2018 Feb; 29(2):255-266. PubMed ID: 29268009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
